FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765937089> ?p ?o ?g. }

• W2765937089 endingPage "144" @default.
• W2765937089 startingPage "144" @default.
• W2765937089 abstract "The efficacy of anti-factor Xa (anti-Xa)-guided dosing of thromboprophylaxis after trauma remains controversial.To assess whether dosing of enoxaparin sodium based on peak anti-Xa levels is associated with the venous thromboembolism (VTE) rate after trauma.Retrospective review of 950 consecutive adults admitted to a single level I trauma intensive care unit for more than 48 hours from December 1, 2014, through March 31, 2017. Within 24 hours of admission, these trauma patients were screened with the Greenfield Risk Assessment Profile (RAP) (possible score range, 0-46). Patients younger than 18 years and those with VTE on admission were excluded, resulting in a study population of 792 patients.The control group received fixed doses of either heparin sodium, 5000 U 3 times a day, or enoxaparin sodium, 30 mg twice a day. The adjustment cohort initially received enoxaparin sodium, 30 mg twice a day. A peak anti-Xa level was drawn 4 hours after the third dose. If the anti-Xa level was 0.2 IU/mL or higher, no adjustment was made. If the anti-Xa level was less than 0.2 IU/mL, each dose was increased by 10 mg. The process was repeated up to a maximum dose of 60 mg twice a day.Rates of VTE were measured. Venous duplex ultrasonography and computed tomographic angiography were used for diagnosis.The study population comprised 792 patients with a mean (SD) age of 46 (19) years and was composed of 598 men (75.5%). The control group comprised 570 patients, was older, and had a longer time to thromboprophylaxis initiation. The adjustment group consisted of 222 patients, was more severely injured, and had a longer hospital length of stay. The mean (SD) RAP scores were 9 (4) for the control group and 9 (5) for the adjustment group (P = .28). The VTE rates were similar for both groups (34 patients [6.0%] vs 15 [6.8%]; P = .68). Prophylactic anti-Xa levels were reached in 119 patients (53.6%) in the adjustment group. No difference in VTE rates was observed between those who became prophylactic and those who did not (7 patients [5.9%] vs 8 [7.8%]; P = .58). To control for confounders, 132 patients receiving standard fixed-dose enoxaparin were propensity matched to 84 patients receiving dose-adjusted enoxaparin. The VTE rates remained similar between the control and adjustment groups (3 patients [2.3%] vs 3 [3.6%]; P = .57).Rates of VTE were not reduced with anti-Xa-guided dosing, and almost half of the patients never reached prophylactic anti-Xa levels; achieving those levels did not decrease VTE rates. Thus, other targets, such as platelets, may be necessary to optimize thromboprophylaxis after trauma." @default.
• W2765937089 created "2017-11-10" @default.
• W2765937089 creator A5008412860 @default.
• W2765937089 creator A5010182982 @default.
• W2765937089 creator A5010543104 @default.
• W2765937089 creator A5032540266 @default.
• W2765937089 creator A5044271213 @default.
• W2765937089 creator A5049866004 @default.
• W2765937089 creator A5056061815 @default.
• W2765937089 creator A5059204889 @default.
• W2765937089 creator A5060052396 @default.
• W2765937089 creator A5062854908 @default.
• W2765937089 creator A5071568421 @default.
• W2765937089 date "2018-02-01" @default.
• W2765937089 modified "2023-10-17" @default.
• W2765937089 title "Association of Anti–Factor Xa–Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma" @default.
• W2765937089 cites W1529230089 @default.
• W2765937089 cites W1972498313 @default.
• W2765937089 cites W1973664727 @default.
• W2765937089 cites W1974221014 @default.
• W2765937089 cites W1975757685 @default.
• W2765937089 cites W1978852679 @default.
• W2765937089 cites W1981157313 @default.
• W2765937089 cites W1988608065 @default.
• W2765937089 cites W1992895030 @default.
• W2765937089 cites W1999687045 @default.
• W2765937089 cites W2005400259 @default.
• W2765937089 cites W2024066122 @default.
• W2765937089 cites W2024935966 @default.
• W2765937089 cites W2031550805 @default.
• W2765937089 cites W2033976861 @default.
• W2765937089 cites W2040548093 @default.
• W2765937089 cites W2052443929 @default.
• W2765937089 cites W2053855311 @default.
• W2765937089 cites W2064032048 @default.
• W2765937089 cites W2097567723 @default.
• W2765937089 cites W2135387854 @default.
• W2765937089 cites W2142041696 @default.
• W2765937089 cites W2147642245 @default.
• W2765937089 cites W2156074347 @default.
• W2765937089 cites W2322068631 @default.
• W2765937089 cites W2323036584 @default.
• W2765937089 cites W2334284018 @default.
• W2765937089 cites W2462315700 @default.
• W2765937089 cites W2499626586 @default.
• W2765937089 cites W2516272876 @default.
• W2765937089 cites W2558445192 @default.
• W2765937089 cites W2606711329 @default.
• W2765937089 cites W74018345 @default.
• W2765937089 cites W2335152594 @default.
• W2765937089 doi "https://doi.org/10.1001/jamasurg.2017.3787" @default.
• W2765937089 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5838588" @default.
• W2765937089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29071333" @default.
• W2765937089 hasPublicationYear "2018" @default.
• W2765937089 type Work @default.
• W2765937089 sameAs 2765937089 @default.
• W2765937089 citedByCount "41" @default.
• W2765937089 countsByYear W27659370892019 @default.
• W2765937089 countsByYear W27659370892020 @default.
• W2765937089 countsByYear W27659370892021 @default.
• W2765937089 countsByYear W27659370892022 @default.
• W2765937089 countsByYear W27659370892023 @default.
• W2765937089 crossrefType "journal-article" @default.
• W2765937089 hasAuthorship W2765937089A5008412860 @default.
• W2765937089 hasAuthorship W2765937089A5010182982 @default.
• W2765937089 hasAuthorship W2765937089A5010543104 @default.
• W2765937089 hasAuthorship W2765937089A5032540266 @default.
• W2765937089 hasAuthorship W2765937089A5044271213 @default.
• W2765937089 hasAuthorship W2765937089A5049866004 @default.
• W2765937089 hasAuthorship W2765937089A5056061815 @default.
• W2765937089 hasAuthorship W2765937089A5059204889 @default.
• W2765937089 hasAuthorship W2765937089A5060052396 @default.
• W2765937089 hasAuthorship W2765937089A5062854908 @default.
• W2765937089 hasAuthorship W2765937089A5071568421 @default.
• W2765937089 hasBestOaLocation W27659370891 @default.
• W2765937089 hasConcept C126322002 @default.
• W2765937089 hasConcept C141071460 @default.
• W2765937089 hasConcept C167135981 @default.
• W2765937089 hasConcept C2776376669 @default.
• W2765937089 hasConcept C2776884760 @default.
• W2765937089 hasConcept C2777288759 @default.
• W2765937089 hasConcept C2777557582 @default.
• W2765937089 hasConcept C2778825682 @default.
• W2765937089 hasConcept C2780011451 @default.
• W2765937089 hasConcept C2780868729 @default.
• W2765937089 hasConcept C2908647359 @default.
• W2765937089 hasConcept C42219234 @default.
• W2765937089 hasConcept C71924100 @default.
• W2765937089 hasConcept C99454951 @default.
• W2765937089 hasConceptScore W2765937089C126322002 @default.
• W2765937089 hasConceptScore W2765937089C141071460 @default.
• W2765937089 hasConceptScore W2765937089C167135981 @default.
• W2765937089 hasConceptScore W2765937089C2776376669 @default.
• W2765937089 hasConceptScore W2765937089C2776884760 @default.
• W2765937089 hasConceptScore W2765937089C2777288759 @default.
• W2765937089 hasConceptScore W2765937089C2777557582 @default.
• W2765937089 hasConceptScore W2765937089C2778825682 @default.
• W2765937089 hasConceptScore W2765937089C2780011451 @default.

• next